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 31 
ABSTRACT 32 
 Mounting an effective immune response against cancer requires the activation of innate and adaptive 33 
immune cells. Metastatic melanoma is the most aggressive form of skin cancer. While 34 
immunotherapies have shown a remarkable success in melanoma treatment, patients develop 35 
resistance by mechanisms that include the establishment of an immune suppressive tumour 36 
microenvironment. Thus, understanding how metastatic melanoma cells suppress the immune system 37 
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is vital to develop effective immunotherapies against this disease. In this study, we find macrophages 38 
and dendritic cells are suppressed in metastatic melanoma and that the Ig-CDR-based peptide C36L1 39 
is able to restore macrophages and dendritic cells’ anti-tumorigenic and immunogenic functions and 40 
to inhibit metastatic growth in lungs. Specifically, C36L1 treatment is able to repolarise M2-like 41 
immunosuppressive macrophages into M1-like anti-tumorigenic macrophages, and increase the 42 
number of immunogenic dendritic cells, and activated cytotoxic T cells, while reducing the number 43 
of regulatory T cells and monocytic myeloid derived suppressor cells in metastatic lungs. 44 
Mechanistically, we find that C36L1 directly binds to the MIF receptor CD74 which is expressed on 45 
macrophages and dendritic cells, disturbing CD74 structural dynamics and inhibiting MIF signalling 46 
on these cells. Interfering with MIF-CD74 signalling on macrophages and dendritic cells leads to a 47 
decrease in the expression of immunosuppressive factors from macrophages and an increase in the 48 
capacity of dendritic cells to activate cytotoxic T cells. Our findings suggest that interfering with 49 
MIF-CD74 immunosuppressive signalling in macrophages and dendritic cells, using peptide-based 50 
immunotherapy, can restore the anti-tumour immune response in metastatic melanoma. Our study 51 
provides the rationale for further development of peptide-based therapies to restore the anti-tumour 52 
immune response in metastatic melanoma. 53 
  54 
INTRODUCTION 55 
 Cutaneous melanoma is a cancer that develops from melanocytes generally located in the epidermal 56 
basal cell layer of the skin. At very-early stages, single skin lesions can be promptly excised and the 57 
5-year survival rate of melanoma is 98%. Beyond these stages, however, melanoma can metastasize 58 
to distant organs including lungs, liver, bones and brain, and the 5-year survival rate in stage IV 59 
drastically decreases to 15-20% (1, 2). The aggressiveness of melanoma is associated with a strong 60 
burden of somatic mutations (3), with different neoepitopes making melanoma cells immunogenic 61 
and boosting the immune response (4, 5). In order to evade the immune response, melanomas often 62 
activate negative immune checkpoint regulators (ICRs) such as PD-1 and PD-L1 or CTLA-4 that 63 
inhibit effector T cell  and function in peripheral tissues or lymph nodes, respectively  (6, 7). 64 
Inhibition of the immune checkpoint regulators with anti-PD-1 and anti-CTLA-4 antibodies enables 65 
T-cell-mediated killing of melanoma cells and significantly improved patient outcomes in recent 66 
years (5). However, immune checkpoint inhibitors (ICI) are only effective if effector T cells infiltrate 67 
the tumour. The generation of effector T cells requires the activation and function of antigen 68 
presenting cells (APCs), such as dendritic cells (DCs) and macrophages (8, 9). DCs and macrophages 69 
are cells from the innate immune system that are essential for starting and shaping the immune 70 
response against any damaged tissue, including cancer (7,10).  71 
Tumour associated macrophages (TAMs) are one of the most predominant immune cells in 72 
melanomas, and the number of TAMs inversely correlates with patients’ outcome, in both early and 73 
late stages of melanoma (11). Macrophages can be polarised into M1-like anti-tumorigenic and M2-74 
like immunosuppressive macrophages (12). We, and others, have shown that, in tumours, 75 
macrophages are often polarised into M2-like macrophages that support tumour cell proliferation, 76 
survival, metastasis, resistance to therapy, and suppress the anti-tumour immune response (12-16). 77 
Similarly, DCs can also acquire immunogenic or tolerogenic behaviours depending on their 78 
maturation status (17). Immunogenic DCs support T cell activation and function (17, 18). However, 79 
immunogenic DCs often switch into a tolerogenic phenotype during cancer progression, which 80 
inhibits the activation and function of effector T cells (19, 20). Tumour cells contribute to the 81 
establishment of an immunosuppressive environment by secreting factors that polarise macrophages 82 
into M2-like immunosuppressive macrophages and suppress DCs immunogenic functions leading to 83 
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(7, 16, 21). Thus, understanding how metastatic melanoma suppresses the immune system is vital for 84 
the development of therapies that restore an effective anti-tumour immune response.  85 
Bioactive peptides based on immunoglobulin complementary determining regions (CDRs) are 86 
promising candidates for adjuvant cancer therapy and can stimulate the innate immune system (22-87 
24). We have previously shown that different CDR peptides display anti-tumour activities against 88 
melanoma, and are able to regulate receptors and transcription factors on both tumour cells and 89 
immune cells (24-28). Recently, we identified the C36 VL CDR-1 peptide (C36L1) as an anti-tumour 90 
CDR-based peptide that inhibits metastatic melanoma cells proliferation and growth in vitro and in 91 
vivo (24, 25). However, the mechanism by which C36L1 inhibits metastatic melanoma progression in 92 
a syngeneic model remains unknown.  93 
 94 
In this study, we found that C36L1 inhibits metastatic melanoma only in mice that have a competent 95 
immune system. C36L1 supports M1-like anti-tumorigenic macrophages and restores DCs pro-96 
inflammatory phenotype and immunogenic function. C36L1 activation of macrophages and DCs 97 
results in a significant increase in the infiltration of effector T cells in the metastatic lungs, leading to 98 
a marked decrease in the tumour burden.  99 
 100 
Macrophage migration inhibitory factor (MIF) is an inflammatory cytokine and an important 101 
regulator of the innate immune system. Previous studies have shown that MIF can induce an 102 
immunosuppressive environment that supports melanoma progression (29, 30). However, the 103 
mechanisms by which MIF suppresses the immune cells remain poorly understood. CD74 is the main 104 
receptor for MIF. CD74 is the invariant chain of the MHC-class II and plays an important role in 105 
antigen presentation. CD74 is highly expressed in antigen presenting cells such as macrophages and 106 
DCs (31, 32). Thus, MIF and CD74 are emerging attractive targets for immunotherapy.  107 
 108 
In the present study we show that the C36L1 peptide binds to CD74 in both macrophages and DCs, 109 
disturbing its structural dynamics and inhibiting the MIF-CD74 signalling and the 110 
immunosuppressive effect on macrophages and DCs. These findings highlight the MIF-CD74 axis as 111 
an important mechanism of macrophage and DC immunosuppression in metastatic melanoma, and 112 
provide a rationale for further evaluation of CDR-based peptides as therapeutic agents able to restore 113 
macrophages and DCs’ anti-tumour functions in metastatic melanoma.  114 
 115 
 116 
MATERIALS AND METHODS  117 
Cell culture 118 
Murine melanoma B16F10 cells were cultured in complete RPMI-1640 medium (Thermo Fisher, 119 
Waltham, MA, USA) supplemented with 10 mM N-2-hydroxyethylpiperazine-N2 ethane sulfonic 120 
acid (HEPES), 24 mM sodium bicarbonate, 40 mg/L gentamicin, pH 7.2 and 10% fetal bovine serum 121 
(FBS), at 37°C. Primary macrophages and myeloid DCs were generated from C57BL/6-mice bone-122 
marrows and cultured in complete DMEM–Dulbecco's Modified Eagle Medium (Thermo Fisher) 123 
supplemented with M-CSF1 (10ng/mL) and RPMI-1640 medium supplemented with GM-CSF 124 
(50ng/mL) and IL-4 (25ng/mL), respectively. Cultures were regularly checked for contamination. 125 
Mice and in vivo metastatic melanoma studies 126 
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6-8 Week-old healthy male C57BL/6 (Wild Type, WT) or NOD/Scid/IL-2rγnull (NSG) mice (n=5, 127 
per group) were intravenously challenged with 5 × 10
5
 (for WT) or 5 × 10
4
 (for NSG) syngeneic 128 
B16F10 viable cells in 0.1 mL of RPMI medium without fetal bovine serum (FBS), and treated on 129 
the next day with intraperitoneal (i.p.) doses of 300 μg (10 mg/kg) of C36L1 peptide, for 5 130 
consecutive days, or with control vehicle (PBS). After 14 days, mice were euthanized and lungs were 131 
harvested and assessed for metastatic colonization. The number of metastatic lesions was quantified 132 
using a stereo microscope (Magnification, ×4) (Nikon, Tokyo). 133 
Peptides 134 
Peptides were purchased from Peptide 2.0 (Chantilly, VA, USA). C36L1 peptide 135 
(KSSQSVFYSSNNKNYLA-NH2) and the irrelevant iCDR control peptide (CE48-H2, 136 
INSGGGGTYYADSVKG-NH2) were synthesized with an amide group in the C- terminus, at 95–137 
98% purity, determined by High-performance liquid chromatography (HPLC) using a C18 column 138 
and subsequently analysed by mass spectrometry. 139 
Tissue paraffin immunofluorescence  140 
Deparaffinization and antigen retrieval were performed in mouse melanoma lung metastasis using a 141 
PT-link system (Dako) and stained as previously described (13) The following antibodies were used 142 
for immune stainings: anti-iNOS, anti-CD206, anti-CD103, anti-Ki67, anti-granzyme B, anti-MPO, 143 
anti-CD86, anti-CD68, anti-MHC-II, anti-CD11b, anti-Ly6C, anti-Ly6G, and anti-PD-L1 all 144 
purchased from Abcam; anti-CD11c and anti-F4/80, purchased from Biolegend; anti-Foxp3 (Cell 145 
Signaling); anti-Arg1 (Bioss) and anti-CD8 (Dako) primary antibodies, anti-CD4 (Biolegend) and 146 
anti-CD25 (R&D systems).  followed by fluorescently labelled secondary antibodies. Images were 147 
acquired using an Axio Observer Light Microscope with the Apotome.2 (Zeiss). Metastatic 148 
melanoma lesions were gated by generating a region of interest (ROI) and threshold merge 149 
fluorescence was limited to ROI and calculated using the NIS-Elements Advanced Research 4.0 150 
software (Nikon, Tokyo). 151 
Flow cytometry analysis  152 
Lungs from C36L1 treated and control mice were digested in collagenase A and purified for CD11c
+
 153 
dendritic cells using a magnetic bead affinity chromatography approach (Miltenyi Biotec, Woking, 154 
UK). Both enriched CD11c
+
 and CD11c
-
 cell fractions were used for DCs and lymphocyte analysis, 155 
respectively. Dendritic cells were stained with anti-CD11c (V450), anti-CD86 (PE-Cy7), anti-MHC-156 
II (V500), anti-CD197 (PERCP-CY5.5). Tumour-infiltrating lymphocytes were characterised using 157 
anti-CD3 (PE), anti-CD4 (FITC), anti-CD8 (FITC) and anti-NK1.1 (FITC). To analyse splenic Treg 158 
cells and macrophages, fresh spleens were obtained from mice after treatments and probed with the 159 
following conjugated antibodies: anti-CD4 (FITC) and anti-Foxp3 (APC) for lymphocyte analysis, 160 
anti-F4/80 (FITC), anti-CD86 (PE-Cy7) and anti-CD40 (APC) for macrophage analysis. All 161 
antibodies were purchased from BD Pharmingen (Franklin Lakes, NJ, USA). Samples were analysed 162 
by flow cytometry using a FACSCanto II (Becton Dickinson, San Jose, CA, USA). Acquired data 163 
was analysed using the FlowJo V10 software (TreeStar Inc., Ashland, OR, USA). 164 
TGF- ELISA assay 165 
CD11c
+
 DCs (1x10
5
) were purified from lymphoid tissues of C36L1 treated mice and control vehicle 166 
(PBS) using the mouse Pan Dendritic Cell Isolation Kit according to manufacturer’s instructions 167 
(Miltenyi Biotec, Bergisch Gladbach, Germany). Primary myeloid DCs were cultured for 48h at 168 
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37°C and the supernatant was collected for TGF- quantification using the mouse-TGF-beta ELISA 169 
Set (BD, OptEIA ™) detection kit according to the manufacturer’s instruction. 170 
Tumour conditioned medium preparation 171 
B16F10 melanoma cells were cultured in 175 cm
2
 culture flasks and in complete RPMI-1640. When 172 
cells reached 70% of confluence, the medium was harvested, filtered for functional assays or 173 
concentrated using StrataClean Resin (Agilent Technologies) for MIF detection by immunoblot. 174 
Alternatively, to increase the concentration of tumour-secreted factors, B16F10 cells were sub-175 
cultured in TCM and fresh media (v/v). 176 
Generation of bone marrow derived macrophages and myeloid dendritic cells 177 
Bone marrow cells were isolated from the femurs of C57BL/6 mice in cold MAC buffer (Ca
2+
, Mg
2+
 178 
free PBS + 2 mM EDTA + 0.5% BSA), centrifuged at 1200 rpm for 10 min, re-suspended in 5 mL 179 
RBC Lysis Buffer (1X, BD Pharm Lyse) and incubated for 5 min at RT. Reaction was terminated in 180 
PBS and cells were centrifuged at 1200 rpm for 10 min at RT. Cells were re-suspended in 5 mL of 181 
MAC buffer and carefully added in the top of 5 mL of Histopaque solution (Sigma-Aldrich) in 15 182 
mL tubes and centrifuged at 1200 rpm, 25 min at 15°C without brake and 1 acceleration. The 183 
monocyte-enriched fraction was collected in a new tube and washed in PBS. Monocytes were further 184 
incubated with M-CSF-1 (10 ng/mL) in complete DMEM media (Thermo Fisher) to generate 185 
macrophages (13), or GM-CSF (50ng/mL) plus IL-4 (25ng/mL) in complete RPMI to generate 186 
myeloid DCs (17, 33). To generate macrophage conditioned media (MCM) for the experiment 187 
described in figure 6, macrophages were incubated with TCM, MIF (200ng/mL) or left untreated, in 188 
the presence or absence of C36L1 peptide (200 M) for 72h, and further incubated in serum free 189 
medium for 48h. Then, the medium was harvested, centrifuged and filtered for functional assays or 190 
stored at -20 °C. 191 
CD8
+
 T cells isolation from naïve splenocytes 192 
Lymphocytes were obtained from fresh spleens of naïve mice. The negative CD8a
+
 T Cell Isolation 193 
Kit (Miltenyi Biotec, Woking, UK) was used to purify CD8+ naïve lymphocytes as per 194 
manufacturer’s instructions.  195 
Flow cytometry analysis of primary DCs 196 
For flow cytometry analysis of primary myeloid DCs, cells were harvested from cultures and blocked 197 
with PBS/BSA 1% plus TruStain fcX anti-mouse CD16/32 (Biolegend) and stained using the 198 
following conjugated antibodies: DCs: anti-CD11c (APC), anti-CD11b (FITC), anti-MHC-II (Percp-199 
Cy5.5), anti-CD80 (PE-Cy7), anti-CD86 (PE), all purchased from Biolegend. Stained cells were 200 
acquired using Attune™ NxT Acoustic Focusing Cytometer (Thermo Fisher). Data analysis was 201 
performed using FlowJo software (Tree Star, Ashland, OR, USA).  202 
Immunofluorescence and confocal microscopy 203 
Fluorescence microscopy of B16F10 cells was performed using the following antibodies: rabbit anti-204 
MIF antibody (Abcam) and secondary antibody solution (anti-rabbit IgG Alexa Fluor 488 (Abcam) 205 
and 10 μg/mL of Hoechst 33342). Confocal microscopy for detection of CD74 interaction with 206 
C36L1 was performed using a biotinylated C36L1. Briefly, tumour cells were incubated with C36L1 207 
(300 µM) and stained using primary mouse-anti-CD74 (Abcam) and a secondary anti-mouse IgG 208 
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Alexa Fluor 488 (Abcam) (Green) and Hoechst 33342 (Blue) (Sigma-Aldrich). Streptavidin-Alexa 209 
Fluor 594 (Red) (LifeTechnology) was used to probe biotinylated C36L1. Fluorescence and confocal 210 
Imaging was performed using an Axio Observer Fluorescence Microscope with the Apotome.2 211 
(Zeiss) and a confocal Zeiss LSM 780 microscope with the 63x 1.4NA objective, respectively. 212 
Colocalization analysis was performed using ImageJ software. 213 
Primary macrophages and myeloid dendritic cells culture assays 214 
Primary macrophages and myeloid DCs were generated as described above. 5x10
5
 cells were seeded 215 
in 12-well plates in complete fresh media and 200 μM of C36L1 peptide was added to the cultures 216 
for at least 6 h prior to the addition of B16F10 TCM or 200 ng/mL of recombinant MIF (R&D 217 
System, Minneapolis, MN, USA). Cells were incubated at 37 
o
C for 72 h and further used in FACs 218 
analysis for phenotyping or functional assays.. 219 
Dendritic cells stimulation for CD8
+
 T cell activation assays 220 
Primary myeloid DCs incubated with C36L1 (200 M) peptide for 6 h prior to incubation with 221 
recombinant MIF at 200 ng/mL for 72 hours. Cells were treated with 200 M of the tyrosinase-222 
related protein 1 (TYRP-1) peptide (NDPIFVLLH) as a MHC class I related melanoma antigen. 223 
CD8
+
 T cells previously incubated with 30U/mL of IL-2 and anti-CD3/CD28 dynabeads (Thermo 224 
Fisher) were co-cultured for 5 days with myeloid DCs in the presence of 30U/mL of IL-12 225 
(PeproTech, London, UK). CD8
+
 T cells were harvested and co-cultured with B16F10 melanoma 226 
cells (10:1) for 72 hours. CD8
+
 T cells were removed from cultures and remaining viable B16F10 227 
cells were quantified with a Neubauer chamber using the Trypan Blue dead cells exclusion stain and 228 
the MTT colorimetric based assay 229 
B16F10 proliferation assay with macrophage conditioned media 230 
To obtain different macrophage conditioned media, primary macrophages were cultured in the 231 
following conditions for 72 h: (1) alone, (2) in the presence of tumour conditioned medium (TCM) or 232 
with recombinant MIF (200 ng/mL) and (3) pre-incubated for 6 h with C36L1 peptide (200 M) 233 
followed by TCM or MIF (200ng/mL) incubation. Next, the medium was removed and macrophages 234 
were further cultured with serum free medium for 48 h to produce macrophage conditioned media 235 
corresponding to the different conditions (MCM1, MCM2 and MCM3). MCM was harvested from 236 
the different macrophage culture conditions, filtered through 0.45 μm and added to 2x103 B16F10 237 
melanoma cells plated in 96-well plates stained with CFSE (Thermo Fisher). B16F10 melanoma cells 238 
were cultured with the different MCMs for 72 h. Next, B16F10 cells were harvested from wells, 239 
stained with propidium iodide (10 g/mL) and the total number of viable (PI-) and proliferating cells 240 
(CFSE
-
) was quantified by flow cytometry acquiring fixed volumes of cell suspension using an 241 
Attune Flow Cytometer.  242 
Quantitative real-time PCR (qPCR) experiments 243 
Total RNA from primary macrophages previously stimulated with C36L1 (200 M) for 6 h and 244 
tumour conditioned media (TCM) from B16F10 melanoma cells or recombinant MIF (200 ng/mL) 245 
for 72 h was isolated using the RNeasy® Mini Kit (Qiagen, Hilden, Germany). cDNA was prepared 246 
from 100ng RNA per sample, and qPCR was performed using gene-specific QuantiTect Assay 247 
primers (Qiagen) following the manufacturer’s instructions. qPCR reactions were performed using 248 
FIREPol® EvaGreen® qPCR Mix Plus ROX (Solis Biodyne, Tartu, Estonia) in a MaxQuant system. 249 
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The following primers were used: TGF- (Mm_Tgfb1_1_SG, Qiagen), IL-10 (Mm_ IL10_1_SG, 250 
Qiagen), PD-L1 (Mm_Pdcd1Ig1 _1_SG, Qiagen), Arginase-1 (Mm_ Arg1_1_SG, Qiagen), IL-6 251 
(Mm_Il6_1_SG, Qiagen), GAPDH (Mm_Gapdh_3_SG, Qiagen). Relative expression levels were 252 
normalized to Gapdh expression according to the formula <2
−(Ctgene of interest −Ctgapdh) (13), and displayed as 253 
fold change units. 254 
Protein extraction and immunoblotting 255 
Primary macrophages and myeloid DCs  were serum starved for 24 hours, treated with C36L1 (200 256 
M) for 6 hours (or left untreated) and stimulated with recombinant MIF (200 ng/mL) at different 257 
time points for determination of AKT and ERK1/2 phosphorylation. Protein lysates were separated 258 
by electrophoresis and immunoblotting analyses were performed for: total AKT, total p44/42 MAPK 259 
(ERK1/2), phospho-AKT (Ser473) and phospho-ERK1/2 (Thr202/Tyr204). HRP-conjugated 260 
secondary antibodies were used, followed by incubation with the ECL substrate (Pierce). All primary 261 
and secondary antibodies were purchased from Cell Signaling Technologies (Beverly, MA, USA). 262 
Anti-GAPDH (Sigma), was used as protein loading control. To assess the presence of MIF in the 263 
tumour conditioned medium (TCM), TCM was filtered with 0.45-μm filter and concentrated using 264 
StrataClean Resin (Agilent Technologies), and immunoblotted for MIF (Abcam). Phosphorylation 265 
ratios were quantified using ImageJ gels’ algorithm, normalized to untreated control lanes. 266 
Peptide/Protein binding prediction 267 
The computational modelling platform Pepsite 2.0 (Russel-Lab) (34) was used to predict the binding 268 
probability of peptides to mouse MIF (PDB: 1MFI, chain B) and mouse CD74 (PDB: 1IIE, chain B) 269 
proteins. Results are displayed as p values, where p ≤ 0.05 values are the statistically significant 270 
binding predictions. iCDR peptide was used as a negative peptide control. Binding probability was 271 
calculated using the interval 0.01 < p < 0.05, where p = 0.01 represents 100% of binding probability 272 
and p > 0.05 represents 0% of binding probability.  273 
C36L1 preparation and molecular dynamics 274 
We obtained the 3D structure of C36L1 by performing de novo structure prediction in Pep-Fold3 275 
web-server. To perform molecular docking experiments, we carried out a molecular dynamics (MD) 276 
simulation on GROMACS 5.1 using CHARMM36 force field. We set up the simulation system on 277 
CHARMM-GUI web-server. We clustered the MD trajectory to obtain a diverse conformational 278 
population to perform molecular docking. All MD frames fitted the reference structure and clustered 279 
with GROMOS method by using GROMACS 5.1, with a backbone root-mean-squared deviation 280 
(RMSD) cutoff of 5.0 Å for C36L1, resulting in 8 different clusters. The centre structure of each 281 
cluster was used in docking simulations. 282 
CD74 normal mode calculations and generation of low-energy conformations 283 
The CD74 structure 1IIE (35) (residues from 118 to 176) was used to perform normal modes analysis 284 
using CHARMM c41b1, and CHARMM36 force filed using DIMB module. A distance dependent 285 
dielectric constant was employed to treat the electrostatic shielding from solvation. The 5 lowest-286 
frequency normal modes were computed as directional constraint to generate low-energy conformers 287 
along the mode trajectory using the VMOD algorithm in CHARMM, as previously described (36, 288 
37). The restraints were applied only on Cα atoms and the energy was computed for all atoms. The 289 
structures were displaced from –3.0 Å to +3.0 Å using steps of 0.1 Å, resulting in 61 intermediate 290 
energy relaxed structures along each mode. 291 
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Molecular docking 292 
Molecular docking simulations were performed using iATTRACT algorithm depicting 293 
conformational selection and induced fit between both partners. Various conformations of both 294 
receptor and ligand (ensemble docking) were simultaneously combined among interface flexibility 295 
and rigid body optimizations during docking energy minimization. The best 50 solutions were written 296 
for each combination. BINANA 1.2 was used to investigate the specific molecular basis guiding the 297 
interaction between CD74 and C36L1. 298 
Chemiluminescent Dot blot binding assay 299 
Interaction between the peptide C36L1 and recombinant CD74 was determined by chemiluminescent 300 
dot-blotting carried out as previously described (24). Briefly, 25 nmoles of C36L1 and the irrelevant 301 
CDR peptide control (iCDR) and vehicle (0.025% DMSO in dH2O) were immobilized on 302 
nitrocellulose membranes, blocked  and incubated with 25 nM of recombinant CD74 (Abcam) 303 
overnight at 4 °C.Membranes were washed and incubated with primary mouse anti-CD74 (Abcam), 304 
washed and incubated with secondary anti-mouse IgG-HRP (CST). Immunoreactivity was 305 
determined using the ECL Western Blotting Substrate (Pierce™) and signal was detected in a 306 
transilluminator Alliance 9.7 (Uvitec, Cambridge UK).  307 
Statistics 308 
All statistic tests were performed using the GraphPad Prism 5.0 software (San Diego, CA). Statistical 309 
differences between experimental and control group were calculated using the Student’s t-test. In 310 
vitro experiments were performed in triplicates. In vivo experiment were performed with at least n=5 311 
per treatment group. Sample size for each experiment is described in figure legends. Significant 312 
differences are indicated by *p < 0.05, **p < 0.01 and ***p < 0.001. 313 
 314 
RESULTS 315 
The Anti-metastatic effect of the C36L1 peptide requires the immune system.  316 
 We have previously shown that intraperitoneal injections of the anti-tumour CDR peptide C36L1 317 
significantly decrease pulmonary melanoma metastasis in a syngeneic model (24, 25). In addition, 318 
bone marrow derived myeloid pro-inflammatory dendritic cells (DCs) displayed equivalent anti-319 
tumour effect when tumor antigen-primed DCs were pre- treated with C36L1 ex vivo and adoptively 320 
transferred to mice bearing lung melanoma metastasis (24). These findings suggest that the anti-321 
tumour effects induced by C36L1 in vivo may result from the peptide ability to stimulate the host 322 
immune response. To further investigate the mechanism of action of C36L1, we treated 323 
immunocompetent C57BL/6 and immunodeficient NOD/Scid/IL-2rγnull mice bearing melanoma 324 
lung metastasis with C36L1 peptide or control vehicle (Figure 1A). We observed that C36L1 325 
significantly decreased lung metastasis in immunocompetent mice but not in immunodeficient mice 326 
(Figure 1B). These findings confirm that C36L1 anti-tumour effect is driven by its ability to stimulate 327 
the immune response against metastatic melanoma. 328 
C36L1 restores macrophages and DCs immunogenic functions in metastatic melanoma. 329 
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 Macrophages and DCs are vital for activating effector T cells and shaping the immune response 330 
against cancer (7). In solid tumours, including melanomas, macrophages and DCs are suppressed by 331 
the tumour and lose their ability to activate and support the immune response against cancer (12, 17). 332 
Tumour associated macrophages (TAMs) often acquire an M2-like phenotype that hampers the anti-333 
tumour immune response and supports tumour growth, metastasis and resistance to therapies (12-14, 334 
38). Similarly, intratumoral DCs often acquire a tolerogenic phenotype and lose their ability to 335 
activate effector T cells (17, 39, 40). Thus, effective anti-cancer immunotherapies must reverse the 336 
tumour immunosuppressive environment and restore the immunogenic functions of macrophages and 337 
DCs. In this respect, we found that C36L1 is able to re-polarise M2-like (F4/80
+
 CD206+ Arg1
+ 
) 338 
tumour associated macrophages into M1-like (F4/80
+
 iNOS
+ 
CD86
+ 
MHC-II
+
) pro-inflammatory and 339 
anti-tumorigenic macrophages (Figure 1C and Supplementary Figure 1A, B, C). In addition, 340 
increased levels of M1-like macrophages were also observed in the spleens of C36L1 treated mice, 341 
compared to control treated mice (Supplementary Figure 5A). The number of activated intratumoral 342 
DCs (CD11c
+
, MHC-II
+
, CD197
+
, CD40
+
, CD86
+
 and CD103
+
) in metastatic lungs from C36L1 343 
treated mice was significantly increased compared to control treated mice (Figure 1D and 344 
Supplementary Figure 1D). The number of neutrophils and polymorphonuclear myeloid-derived 345 
suppressor cells did not significantly change between control and C36L1 treated metastatic lungs 346 
(Supplementary Figure 3A and B). However, we observed a small but statistically significant 347 
decrease in the number of monocytic myeloid-derived suppressor cells (Supplementary Figure 3C) 348 
C36L1 treatment decreased the secretion of the immunosuppressive cytokine TGF- by CD11c+ DCs 349 
from lymphoid organs (spleens and cervical lymph nodes) (Supplementary Figure 5B). These 350 
findings suggest that C36L1 re-polarises and re-activates macrophages and DCs’ immunogenic and 351 
anti-tumorigenic functions in metastatic melanoma.  352 
C36L1 increases the level of effector T cells in the TME. 353 
 Tumour specific antigen presentation by DCs and macrophages to effector T cells is a crucial step for 354 
the generation of an effective immune response against cancer, and increased infiltration of effector T 355 
cells in tumours is a good prognostic marker (4, 5). Since treatment with C36L1 decreases melanoma 356 
pulmonary metastasis and increases the numbers of pro-inflammatory macrophages and DCs, we 357 
asked whether C36L1 increases effector T cell infiltration in metastatic tumours. We found that, 358 
indeed, C36L1 significantly increased the levels of CD4
+
 T cells from 6.86% to 13.35%, CD8
+
 359 
cytotoxic T cells from 6.11% to 17.6%, and NK1.1
+
 natural killer cells from 8.44% to 16.13%, in 360 
lung metastatic melanoma (Figure 1E and Supplementary Figure 6A). CD8+ cytotoxic T cells 361 
number and proliferative (CD8+Ki67+) and activation status (CD8+GranzymeB+) were significantly 362 
increased in C36L1 treated metastatic lungs compared to control treated lungs (Supplementary Figure 363 
2 A and B). We also observed a decrease in the number of regulatory T cells (CD4+CD25+FoxP3+)  364 
in metastatic lungs from C36L1 treated mice compared to control mice (Supplementary Figure 2C 365 
and D). In lymphoid organs, tolerogenic DCs are responsible for inducing Foxp3
+ 
Tregs 366 
differentiation by secreting TGF-β. Since C36L1 treatment decreases TGF- production by DCs 367 
(Supplementary Figure 5B), we evaluated whether Tregs were also reduced in lymphoid organs upon 368 
C36L1 treatment. Flow cytometry analysis of mice splenocytes revealed a highly significant decrease 369 
in the percentage of CD4
+
Foxp3
+
 Tregs from 59.6% to 1.39% following C36L1 treatment 370 
(Supplementary Figure 6B). Together, these findings indicate that C36L1 restores DCs and 371 
macrophages immunogenic functions, increases effector T cell infiltration in metastatic tumours and 372 
inhibits immunosuppressive regulatory T cells.  373 
C36L1 inhibits the suppressive effects of tumour-secreted factors in macrophages. 374 
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 Tumour educated macrophages exhibit an M2-like phenotype and support cancer progression in 375 
several ways, including the direct support of cancer cell proliferation (17). To further understand how 376 
C36L1 affects macrophage function, we cultured metastatic B16F10 melanoma cells with 377 
conditioned media from tumour educated macrophages (macrophages previously exposed to tumour 378 
conditioned media) in the presence or absence of C36L1. As expected, melanoma cells exposed to 379 
tumour educated macrophages showed a significant increase in proliferation. Addition of C36L1 380 
abrogated this macrophage - driven tumour cell proliferation (Figure 2 and Supplementary Figure 381 
6C). These results show that macrophages exposed to tumour conditioned media acquire pro-382 
tumorigenic functions and this can be inhibited by C36L1 peptide. These findings suggest that 383 
C36L1 must interfere with a tumour secreted factor (or its receptor) that regulates macrophage 384 
function.  385 
C36L1 binds to MIF receptor, CD74  386 
 C36L1 is a linear and flexible CDR-based peptide. Linear peptides are likely to adopt a few stable 387 
conformations and interactive possibilities to different relevant targets (41). Previous studies have 388 
shown that stromal and melanoma cells express high levels of MIF, supporting melanoma growth 389 
and modulating immune cells in late-stage melanoma (29, 30, 42-46). Dendritic cells and 390 
macrophages both express MIF’s main receptor,  CD74 (47). Thus, we hypothesize that C36L1 could 391 
interfere with MIF signalling on macrophages and dendritic cells. In agreement with previous 392 
studies, we observed that B16F10 metastatic melanoma cells express and secrete high levels of MIF 393 
in vitro, (Figure 3A, B), and that MIF is highly expressed in small and large lung metastatic 394 
melanoma lesions (Figure 3C). 395 
  396 
 A pilot study addressing the binding probability of C36L1 to MIF and its receptor CD74 was carried 397 
out using the computational modelling prediction of peptide-binding sites to protein surfaces and the 398 
Pepsite 2.0 algorithm (34). This in silico approach predicted a statistically significant binding of 399 
C36L1 to mouse CD74 B chain (PDB: 1IIE) protein (p < 0.001), and a potential binding to mouse 400 
MIF B chain (PDB: 1MFI) protein (p = 0.04) (Figure 4A). No interaction with either CD74 or MIF 401 
was predicted for an irrelevant control CDR peptide (iCDR - CE48-H2), which was previously 402 
observed to have no effect on metastatic melanoma proliferation in vitro and progression in vivo (25) 403 
(Figure 4A and Supplementary Figure 7A). We used the Pepsite 2.0 algorithm to identify the amino 404 
acid residues involved in the interaction of C36L1 to CD74, and found that the peptide is predicted to 405 
interact with Tyr (118), Arg (179) and His (180) residues from the B chain of the murine/human 406 
CD74 protein, highlighted in red (Supplementary Figure 7B). Interestingly, Mesa-Romero et al., have 407 
recently described that some of these residues (highlighted in green) are also critical for the 408 
interaction of MIF with the CD74 antagonist (RTL-1000) (48). The in silico predicted interaction of 409 
C36L1 with CD74 was further confirmed in a dot-blot binding assay using both immobilized C36L1 410 
and iCDR peptides against recombinant murine CD74 protein (Figure 4B). These results suggest that 411 
C36L1 could act as an antagonist of MIF, since its interaction occurs on critical binding sites used by 412 
MIF to interact with CD74.  413 
  414 
 To further investigate this, we performed a molecular docking study between C36L1 and CD74 415 
protein. Docking calculations resulted in 122,000 different poses of which the worst 1% were 416 
discarded for presenting outliers’ energy values. The average energy of remaining structures was 60.8 417 
kcal/mol and more than 95% of them presented thermodynamically favourable binding energies 418 
(Supplementary Figure 7C). The best solution occurred between C36L1 cluster 5 centroid and a 419 
CD74 structure with large opening (2.7 Å from reference) along normal mode 10, which shows an 420 
open-close motion. This pose presented -192.6 kcal/mol as free energy of binding, and is depicted in 421 
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Supplementary Figure 7D. The key interaction elements observed in this complex were analysed 422 
using BINANA algorithm. Hydrophobic contacts forming an extended pocket along the interface of 423 
all CD74 subunits were observed (Figure 4C). Stronger interactions were also observed:  three 424 
critical hydrogen bonds, one salt-bridge and one cation-π stacking interaction between CD74 and 425 
C36L1 peptide (Table 1 and Figure 4D). Interestingly, C36L1 cluster 5 centroid appears in 30 of top 426 
50 best poses suggesting that this peptide conformation is likely to be privileged to bind CD74. 427 
Moreover, structures with large displacements along mode 10 of CD74 are more frequent; the worst 428 
ranked structures were less displaced. C36L1 interacts better with CD74 as it moves according to 429 
normal mode 10, whereas once CD74 returns to the relaxed conformation, the peptide binding 430 
affinity decreases and the complex dissociates. Furthermore, the overlap of 50 best solutions showed 431 
a putative preferred binding region of C36L1 to the interface formed between N- and C-terminal 432 
portions of CD74 monomers. This binding site is corroborated by the observation of C36L1 main 433 
binding to CD74’ α-helices, only in the worst solutions. In Figure 4E, blue arrows indicate spatial 434 
distribution of C36L1 (blue) over CD74 altered structures (green) and the best and worst poses of 435 
C36L1 are shown in red.  A video representing the consequences of this dynamic interaction between 436 
C36L1 and CD74 tertiary structure is shown in Supplementary Video 1.  437 
C36L1 binds to CD74 on macrophages and DCs and disrupts downstream signalling. 438 
 CD74 is a transmembrane protein mainly expressed in APCs and associated with the MHC II 439 
intracellular trafficking. CD74 is the main receptor for MIF in macrophages and DCs, and MIF 440 
binding to CD74 leads to immunosuppression of macrophages, activation of myeloid derived 441 
suppressor cells (MDSCs), suppression of natural killer (NK) cells and inhibition of T cell activation 442 
(29, 43, 47, 49-51). Thus, we evaluated whether C36L1 peptide (as predicted in the in silico 443 
approach) physiologically binds to CD74 receptor on macrophages and DCs.  444 
  445 
 To address these interactions, primary bone marrow derived macrophages and DCs were incubated 446 
with biotinylated C36L1 probed with streptavidin-PE (Red), and stained for CD74 (green). We 447 
observed that C36L1 binds to CD74 in both macrophages and DCs (Figure 5A). CD74 can be 448 
expressed intracellularly and at the plasma membrane. Using confocal microscopy, we observed that 449 
C36L1 co-localizes with CD74 both intracellularly and at the cell membrane (Figure 5B). MIF 450 
interaction with CD74 receptor activates different cell signalling pathways, including the PI3K/AKT 451 
and the MAPK signalling pathways (47, 49, 52). In agreement with this, we observed that 452 
recombinant MIF induces the phosphorylation of AKT (S473) and ERK (Thr202/Tyr204) in both 453 
primary macrophages and DCs (Figure 5C). However, pre-incubation of macrophages and DCs with 454 
C36L1 inhibited MIF induced AKT and ERK downstream signalling on macrophages and DCs. 455 
These findings show that C36L1 binds to CD74 on macrophages and DCs and disrupts MIF-CD74 456 
signalling on these cells.  457 
C36L1 inhibits MIF induced suppression of macrophages and DCs and restores their 458 
immunogenic and anti-tumorigenic functions. 459 
 To further understand the mechanism of action of C36L1 on macrophages, we evaluated the 460 
immunosuppressive and tumour supporting functions of macrophages exposed to MIF in the 461 
presence or absence of C36L1. Macrophages exposed to MIF supported the proliferation of 462 
melanoma cells (similar to what we observed when we exposed macrophages to tumour conditioned 463 
media (TCM) in Figure 2). C36L1 treatment abolished this MIF-induced pro-tumorigenic function of 464 
macrophages (Figure 6A). C36L1 also significantly decreased the expression of the 465 
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immunosuppressive factors TGF-, IL-10, IL-6, Arginase-1, PD-L1 by macrophages exposed to MIF 466 
(Figure 6B).  467 
  468 
 To understand the mechanism of action of C36L1 on DCs, we evaluated the expression levels of DC 469 
activation markers as well as DCs ability to activate cytotoxic T cells in the presence or absence of 470 
MIF and C36L1 (Figure 6C). Treatment of primary myeloid DCs with MIF significantly decreased 471 
the levels of the maturation and co-stimulatory markers CD86, CD80 and MHC-II. Treatment with 472 
C36L1 peptide counteracted the immunosuppressive effect of MIF on DCs (Figure 6D). DCs ability 473 
to activate cytotoxic T cell killing function was also significantly impaired by MIF but rescued by 474 
C36L1 treatment (Figure 6C, E, Supplementary Figure 8). All together, these results provide 475 
functional evidence that C36L1 restores DCs and macrophages immunogenic and anti-tumorigenic 476 
functions by interfering with the MIF/CD74 immunosuppressive signalling axis.  477 
DISCUSSION  478 
Cutaneous melanomas are common in the Western hemisphere causing the majority (75%) of deaths 479 
related to skin cancer (53). The incidence rate of melanoma increases faster than for any other cancer 480 
(52). At very-early stages, melanomas can be surgically removed and the 5-year survival rate of 481 
melanoma is 98%. However, melanoma can metastasize to distant organs including lungs, liver, 482 
bones and brain, and the 5-year survival rate of patients with metastatic melanoma drastically 483 
decreases to 15-20% (1, 2).Treatment with immune checkpoint inhibitors has significantly increased 484 
the 5-year survival rate of melanoma patients (1, 55), but the number of non-responders is still high, 485 
with the lack of response being currently intensively investigated.  Mutations of gene families of 486 
cytokines, chemokine levels, mesenchymal transition, E-cadherin and other proteins expressed in 487 
tumours are being studied (56). Understanding and targeting the immunosuppressive tumour 488 
microenvironment to restore an anti-tumour immune response is an area of great interest (7, 29, 57, 489 
58). Therefore, understanding the mechanisms by which metastatic melanoma suppresses anti-490 
tumour immunity could further contribute to the development of new combinatorial agents that 491 
restore the immune response against metastatic melanoma. 492 
 Synthetic peptides based on Immunoglobulin-CDR sequences have shown promising anti-tumour 493 
properties, and some of these peptides display immune stimulatory functions (22, 24-26).  494 
 We previously found that the C36 VL CDR1 peptide (C36L1) displays dose-dependent antitumor 495 
activities in vitro against B16F10 melanoma cells, exerting microtubule de-polymerization at low 496 
concentrations and cell death at high concentrations (24). Our in vivo studies show that the anti-497 
tumour effect induced by the C36L1 peptide strictly depends on its original sequence since the 498 
shuffled peptide was unable to exert any anti-tumour effects in the metastatic melanoma setting, and 499 
acted in a similar way as the PBS vehicle control (24). We also observed that the anti-tumour activity 500 
of C36L1 is not a general property of Ig-CDRs, since other CDR sequences (i.e. CE48-H2) did not 501 
show such anti-tumour effects (25). Short peptides can interact with more than one ligand, with 502 
variable affinities under different conditions or microenvironments. We have previously uncovered 503 
peptide sequences that exert different therapeutic activities against infection diseases and cancer (22, 504 
26, 27).  505 
 In this study, we uncover the mechanism by which C36L1 restores an effective immune response 506 
against metastatic melanoma in vivo. We found that C36L1 is able to decrease melanoma metastatic 507 
growth in wildtype mice but not in immunodeficient mice, suggesting that in vivo, the anti-tumour 508 
effect of C36L1 requires the immune system. Specifically, we found that C36L1 is able to re-polarise 509 
M2-like immunosuppressive tumour associated macrophages into immunogenic and anti-tumorigenic 510 
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M1-like macrophages. C36L1 also promotes the activation and immunogenicity of DCs. C36L1 511 
driven activation of the innate immune system leads to the inhibition of immunosuppressive Tregs, 512 
the activation of effector T cells and subsequently to the killing of metastatic melanoma cells. 513 
Mechanistically, we found that C36L1 binds to the MIF receptor CD74 on macrophages and DCs, 514 
thereby inhibiting MIF immunosuppressive effect on these innate immune cells, and shifting the 515 
balance from an immunosuppressive tumour microenvironment into a pro-inflammatory 516 
immunogenic environment in which the anti-tumour immune response is reinvigorated.  517 
  518 
 Tumours, including melanomas secrete factors that inhibit the immune system. Among these factors, 519 
MIF has been recently shown to have immunosuppressive activities, in many cancers, including 520 
glioblastoma, breast, pancreatic cancer and melanoma (29, 30, 49, 59-61). Thus, MIF is an emerging 521 
attractive target for immunotherapy. In pancreatic cancer, MIF is an important downstream regulator 522 
of fibrosis that culminates in the recruitment of TAMs favouring metastasis (21). In a similar way, 523 
metastatic uveal melanoma cells secrete MIF to recreate the eye immune-privileged environment and 524 
to inhibit the immune response in the liver, favouring liver metastasis (42, 61). In cutaneous 525 
melanoma, MIF is produced by melanoma cells to support growth and induce immunosuppression 526 
(29, 51). However, the role of MIF in metastatic melanoma remains unclear. In glioblastoma, MIF 527 
can also induce pro-inflammatory functions, including M1-like macrophage polarization (59, 63). 528 
Bevacizumab, a monoclonal antibody that targets VEGF may also interact and neutralize MIF in 529 
glioblastomas, inducing the polarisation of macrophages into the M2-like phenotype that contributes 530 
to therapy resistance (59). This dual and opposite effect of MIF on the immune response depends on 531 
the cytokine milieu in the tumour microenvironment and on the levels of MIF. In fact, very low or 532 
high concentrations of MIF are thought to suppress the immune response, while intermediate doses 533 
rather  promote pro-inflammatory and anti-tumour effects (59).  534 
  535 
Different drugs targeting MIF and its main receptor CD74 are in clinical development in many 536 
diseases, including cancer (31, 32, 48, 64-67). The MIF inhibitor 4-iPP is so far the only 537 
immunomodulatory agent described to be effective in melanoma, and has shown promising results in 538 
subcutaneous melanoma, associated to an increase in monocyte pro-inflammatory functions (30). The 539 
effect of blocking MIF-CD74 signalling in metastatic melanoma has not yet been investigated. 540 
Targeting CD74 seems to be a promising anti-cancer therapeutic strategy to disrupt MIF induced 541 
suppressive signalling effect on monocytes (31, 49, 67). The most well-characterized CD74 inhibitor 542 
is Milatuzumab, a monoclonal antibody approved for the treatment of chronic lymphocytic leukaemia 543 
with acceptable side effects in humans including leukopenia, rash, nausea and vomiting at low grade 544 
(67). In the field of drug discovery, peptide based approaches emerge with intrinsic advantages, 545 
compared to antibodies including their small size, lack of immunogenicity, high affinity, specificity 546 
to different targets, low toxicity, good tissue penetration and biocompatibility (22, 25, 26). Peptides 547 
can exert immunomodulatory functions and have been shown to neutralize immune checkpoint 548 
receptors in cancer (68-70). Indeed, linear peptides such as CDR peptides are flexible and likely to 549 
bind to different biologically relevant targets (41). Ig-CDR peptides, like C36L1, are mostly nontoxic 550 
in normal tissues and untransformed cell lines and are short living in the plasma due to proteolysis 551 
and renal filtration. However, since they can promptly interact with immune cells such as dendritic 552 
cells and macrophages, they could modulate the immune response in advanced stage melanomas.  553 
 554 
In this study, we found that C36L1 interaction with the CD74 receptor expressed on macrophages 555 
and DCs is sufficient to inhibit MIF-CD74 signalling and to restore macrophages and DCs anti-556 
tumorigenic functions (Figure 7). Our in silico studies show that the flexibility of this linear peptide 557 
allows its transient interaction with the CD74 receptor, disturbing its molecular dynamics in the cell 558 
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membrane. C36L1-CD74 interaction seems to be crucial to disrupt CD74 interaction with MIF in 559 
both macrophages and DCs. The cell internalisation of CD74 conjugates is a well-known 560 
pharmacological characteristic of CD74 (50, 67), which has been recently explored as a drug-carrier 561 
strategy for the treatment of lymphomas and B cell malignancies (67). CD74 internalisation 562 
independent of MIF binding could impair the activation of downstream signalling (31, 71). In this 563 
respect, we found that C36L1 binds to CD74 at the cell membrane as well as in the intra-cellular 564 
space of macrophages and DCs. This suggests that C36L1 binding to CD74 may promote its 565 
cytosolic internalization making it unavailable for binding to MIF. MIF binding to CD74 activates 566 
the PI3K/AKT and MAPK signalling pathways, and both these pathways have been related to 567 
monocyte immunosuppression, and macrophage M2-like polarization (45, 47, 49, 52). In agreement 568 
with these studies, we found that C36L1 inhibits MIF induced AKT and ERK1/2 phosphorylation in 569 
both primary macrophages and DCs and restores their anti-tumorigenic and immunogenic functions 570 
(Figure 7). 571 
  572 
In conclusion, our findings suggest that MIF is highly secreted in metastatic melanoma and is an 573 
important immunosuppressor of macrophages and DCs.  Blocking MIF signalling through CD74 on 574 
macrophages and DCs, using the C36L1 Ig-CDR-based peptide, restores the pro-inflammatory 575 
functions of macrophages and DCs thereby harnessing the immune response against metastatic 576 
melanoma. This study provides a rationale for further evaluation of CDR-based peptides as 577 
therapeutic agents to restore the ability of macrophages and DCs to start and shape an effective anti-578 
cancer immune response.  579 
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 843 
FIGURE LEGENDS 844 
Figure 1. The anti-metastatic effect of the C36L1 peptide depends on the immune system. (A) 845 
Metastatic melanoma model and therapeutic strategy using C36L1 peptide and control vehicle (PBS). 846 
At end point, lungs, cervical lymph nodes and spleens are harvested. (B) Number of metastatic foci 847 
in immunocompetent (Wild Type, WT) and immunodeficient (NOD/Scid/IL-2rγnull, NSG) mice 848 
treated with control vehicle (PBS) or C36L1 peptide. n = 10 mice per group (two combined 849 
experiments). Values are expressed as means ± s.e.m., and were analysed using a two-tailed unpaired 850 
t-test. ** p=0.001. Graph combines two independent experiments. (C) Left, Immunofluorescent 851 
staining and quantification of F4/80
+
Arg.1
+
 M2-like and F4/80
+
iNOS
+
 M1-like macrophages in lung 852 
metastasis from C36L1 and control vehicle treated mice. Melanoma lung metastatic area appears in 853 
dark/brown colour in brightfield images. Right, Graphs show quantification of positive F4/80
+
Arg1
+
 854 
(*p=0.028) and F4/80
+
iNOS
+
 (*p=0.02) stainings. Nuclei were counterstained with Hoechst 33342 855 
(Blue). N = 5 mice per group; at least five fields assessed per sample. Values are expressed as means 856 
± s.e.m., and were analysed using a two-tailed unpaired t-test. Blue and red lines indicate the tumour 857 
area in C36L1 and control vehicle treated mice, respectively. Scale bars: 50 μm. (D) Flow Cytometry 858 
quantification of activation markers MHC-II (**p=0.003), CD197 (**p=0.002), CD86 (*p=0.019), 859 
and CD40 (**p=0.007) expressed in CD11c
+
 DCs isolated from lungs of C36L1 and control vehicle 860 
treated mice. Data represent quantification of four independent experiments with 5 pooled lungs per 861 
group for each experiment. Values are expressed as means ± s.e.m, and were analysed using a two-862 
tailed, unpaired t-test. (E) Quantification of CD4
+
 (*p=0.03), CD8
+
 (**p=0.005) and NK1.1
+
 863 
(*p=0.02) cells among CD3
+
 cells in lung metastatic lesions from C36L1 and control vehicle treated 864 
mice. Bar graphs combine three independent in vivo experiments with 5 pooled lungs per group for 865 
each experiment. Values represent means ± s.e.m., and were analysed using a two-tailed unpaired t-866 
test. 867 
Figure 2: C36L1 counteracts the pro-tumorigenic activity of macrophages induced by 868 
melanoma derived factors. Left: Schematics describing the workflow of the tumour cell 869 
proliferation assay. Tumour cells are exposed to either conditioned media from: untreated 870 
macrophages (MCM1), macrophages exposed to tumour conditioned media (TCM) from metastatic 871 
melanoma B16F10 cells (MCM2), or macrophages exposed to C36L1 peptide + TCM from B16F10 872 
cells (MCM3). Next, MCM generated from these three conditions were added into B16F10 873 
melanoma cells and the number of live proliferating cells was quantified by flow cytometry after 72h. 874 
Right: Bar graph represents average of three independent experiments (n=3). Values represent means 875 
± s.e.m. and data were analysed using a two-tailed unpaired t-test. *** p<0.001. 876 
Figure 3: MIF is secreted by B16F10 metastatic melanoma cells and is highly expressed in lung 877 
metastatic lesions. (A) Immunofluorescent staining of B16F10 cells stained for MIF (green) and 878 
nuclei (blue). Scale bars: 50 μm. (B) Immunoblotting analysis of B16F10 tumour conditioned media 879 
 
21 
(TCM) detecting secreted MIF. (C) Immunohistochemical staining of lung melanoma metastasis 880 
showing MIF (in red) in small and large lesions. Dark brown areas are metastatic foci of melanoma 881 
cells. Scale bars: 200 μm (Left) and 50 μm (Right). 882 
Figure 4: Binding prediction and molecular docking of C36L1 dynamic interactions to MIF 883 
and its receptor CD74. (A) Binding probability of C36L1 peptide and irrelevant peptide (iCDR) to 884 
MIF and its receptor CD74 calculated using Pepsite algorithm. Best ranked binding scores (n=5) 885 
were included in the analysis for each group (*** p< 0.001). (B) Dot-blot binding assay for C36L1 886 
and iCDR peptides to mouse recombinant CD74. Bar graph represents mean of RLU in dot area 887 
quantified using ImageJ software from triplicates (n = 3), ***p < 0.001). (C) Hydrophobic pocket 888 
(orange) formed by CD74 and C36L1 partners characterized by carbon-carbon interactions above a 889 
4Å distance cut-off. (D) Electrostatic interactions between CD74 and C36L1 peptide: hydrogen 890 
bonds formed between partners. Donor-acceptor distances are described; salt bridge formed 891 
involving K13; cation-π stacking between tyrosine residues of chain A of CD74 and C36L1. CD74 892 
chains A, B and C are coloured in green, cyan and magenta, respectively. C36L1 is coloured in 893 
yellow. (E) Overlap of highest and lowest free energy results for C36L1 (cyan) in complex with 894 
CD74 (green). Left: Overlap of the lowest free energy 50 poses showing major concentration of 895 
C36L1 peptide at the CD74 N- and C- terminal interface. Lowest peptide free energy pose 896 
highlighted in red. Right: Overlap of the lowest free energy 50 poses, where C36L1 visits other 897 
regions of CD74, including the external region of the α-helices. Lowest peptide free energy 898 
highlighted in red. 899 
Figure 5: C36L1 interacts with CD74 in both macrophages and dendritic cells, and inhibits 900 
MIF/CD74 signalling. (A) Immunofluorescent staining of C36L1 (red), CD74 (green), nuclei (blue) 901 
in primary macrophages (MOs) and dendritic cells (DCs). CD74 interactions with C36L1 were 902 
quantified using automated analysis in ImageJ. Arrows indicate merged channels depicted in white. 903 
Four fields per slide were quantified. Scale bars: 50 μm. (B) Representative fluorescent confocal 904 
microscopy images showing colocalisation of C36L1 peptide (Red) and CD74 (green) in the 905 
intracellular and surface focal plane of both primary macrophages (left) and DCs (right). Co-906 
localized points were detected using ImageJ colocalization algorithm, depicted in white. Scale bars: 907 
10 μm. (C) Immunoblotting analysis of phosphorylated AKT and ERK1/2 on primary macrophages 908 
(10 and 20 min, respectively) and DCs (5 mins) previously treated with C36L1 (200 g/mL) or left 909 
untreated, and further treated with recombinant MIF (200 ng/mL).  910 
Figure 6: C36L1 blocks MIF induced immunosuppressive effect on macrophages and dendritic 911 
cells. (A) Top: Schematics describing the workflow of the tumour cell proliferation assay. B16F10 912 
metastatic melanoma cells are exposed to conditioned media from: untreated macrophages, 913 
macrophages exposed to MIF (200 ng/mL) or macrophages exposed to C36L1 (200 g/mL) + MIF 914 
(200ng/mL).  The number of live proliferating B16F10 cells was quantified by flow cytometry after 915 
72h. Bottom: Bar graph represents average of three independent experiments (n=3), mean ± s.e.m. 916 
Data were analysed using a two-tailed unpaired t-test (*** p<0.001). (B) C36L1 blocks MIF induced 917 
immunosuppressive effect on primary macrophages. mRNA levels of TGF- (n.s = 0.058), IL-10 918 
(*p=0.049, p=0.042), Arg.1 (**p=0.002, ***p<0.001), PD-L1 (**p=0.0049, ***p<0.001), and IL-6 919 
(**0.0015, ***p<0.001) from macrophages exposed to recombinant MIF in the presence or absence 920 
of C36L1 peptide. Experiment was performed in triplicates (n=3). Values represent mean ± s.e.m and 921 
were analysed using a two-tailed unpaired t-test. (C) Schematics describing the different conditions 922 
in which DCs were cultured and then used to activate T cells. Primary DCs were incubated with MIF 923 
(200 ng/mL) in the presence or absence of C36L1 peptide and activation markers were quantified by 924 
flow cytometry. These DCs were further pulsed with a melanoma antigen peptide and incubated with 925 
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syngeneic purified CD8
+
 T cells. Next, T cells were harvested and incubated with melanoma B16F10 926 
cells at a ratio of 10/1 CD8
+
 T cells/ B16F10 tumour cell. (D): Quantification of MHC-II (p=0.01), 927 
CD80 (p<0.001) and CD86 (p=0.02) activation markers in DCs performed by flow cytometry. Bar 928 
graph represents mean ± s.e.m, from three independent experiments (n=3). Data were analysed using 929 
a two-tailed unpaired t-test. (E) Bar graph showing the quantification of dead B16F10 cells after 930 
incubation with CD8
+
 T cells. Best of three independent experiments is shown, mean ± s.e.m from 931 
biological triplicates, one-tailed unpaired t-test (*p=0.032). 932 
Figure 7: Scheme of the mechanism of action of the C36L1 peptide in macrophages and 933 
dendritic cells. C36L1 binds to MIF’s receptor CD74, thereby blocking its immunosuppressive 934 
effect on macrophages and DCs, restoring their anti-tumorigenic functions and their capacity to 935 
activate and support an effective immune response against metastatic melanoma. 936 
 937 
